絞り込み

16530

広告

大飯原発訴訟 住民側が上告断念 敗訴確定へ

福井県にある大飯原子力発電所3号機と4号機について、住民らが関西電力に運転しないよう求めた裁判で、住民側は、17日、最高裁判所に上告しない方針を明らかにしました...

  1. 西日本豪雨の災害ごみ、中川環境相「広域処...
  2. ジェームズ・ウェッブ宇宙望遠鏡、今年2度...
  3. 版画・彫刻家の浜田知明さん死去 戦争テー...
  4. 俳優の生田悦子さん死去 (NHK)

ニュース一覧

Antibiotic susceptibility, heteroresistance, and updated treatment strategies in Helicobacter pylori infection.

著者 Mascellino MT , Porowska B , De Angelis M , Oliva A
Drug Des Devel Ther.2017 ; 11():2209-2220.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (143view , 0users)

Full Text Sources

Medical

Miscellaneous

In this review, we discuss the problem of antibiotic resistance, heteroresistance, the utility of cultures and antibiotic susceptibility tests in Helicobacter pylori (Hp) eradication, as well as the updated treatment strategies for this infection. The prevalence of antibiotic resistance is increasing all over the world, especially for metronidazole and clarithromycin, because of their heavy use in some geographical areas. Heteroresistance (simultaneous presence of both susceptible and resistant strains in different sites of a single stomach) is another important issue, as an isolate could be mistakenly considered susceptible if a single biopsy is used for antimicrobial tests. We also examined literature data regarding eradication success rates of culture-guided and empiric therapies. The empiric therapy and the one based on susceptibility testing, in Hp eradication, may depend on several factors such as concomitant diseases, the number of previous antibiotic treatments, differences in bacterial virulence in individuals with positive or negative cultures, together with local antibiotic resistance patterns in real-world settings. Updated treatment strategies in Hp infection presented in the guidelines of the Toronto Consensus Group (2016) are reported. These suggest to prolong eradication therapy up to 14 days, replacing the old triple therapy with a quadruple therapy based on proton pump inhibitor (PPI), bismuth, metronidazole, and tetracycline for most of the patients, or as an alternative quadruple therapy without bismuth, based on the use of PPI, amoxicillin, metronidazole, and clarithromycin. The new drug vonoprazan, a first-in-class potassium-competitive acid blocker recently approved in Japan, is also considered to be a promising solution for Hp eradication, even for clarithromycin-resistant strains. Furthermore, there is growing interest in finding new therapeutic strategies, such as the development of vaccines or the use of natural resources, including probiotics, plants, or nutraceuticals.
PMID: 28814829 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード